Page last updated: 2024-08-21

benzoxazoles and Multiple Myeloma

benzoxazoles has been researched along with Multiple Myeloma in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baranowska, KA; Børset, M; Holien, T; Klein, DC; Misund, K; Rampa, C; Sundan, A; Waage, A	1
Aki-Yalcin, E; Beksac, M; Ertan-Bolelli, T; Hidayat, AN; Tian, E; Usmani, SZ; Yalcin, I	1
Berdeja, JG; Ghobrial, IM; Neuwirth, R; Patel, CG; Richardson, PG; Siegel, DS; Vij, R; Wolf, JL; Zohren, F	1
Arnold, L; Franck, B; Gulliya, KS; Matthews, JL; Schneider, U; Sharma, R	1

Trials

1 trial(s) available for benzoxazoles and Multiple Myeloma

Article	Year
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. American journal of hematology, 2016, Volume: 91, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzoxazoles; Drug Monitoring; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Middle Aged; Multiple Myeloma; Multiprotein Complexes; Neoplasm Grading; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Retreatment; TOR Serine-Threonine Kinases; Treatment Outcome; Waldenstrom Macroglobulinemia	2016

Article

Year

TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.

American journal of hematology, 2016, Volume: 91, Issue:4

Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzoxazoles; Drug Monitoring; Female; Humans; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Middle Aged; Multiple Myeloma; Multiprotein Complexes; Neoplasm Grading; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Retreatment; TOR Serine-Threonine Kinases; Treatment Outcome; Waldenstrom Macroglobulinemia

2016

Other Studies

3 other study(ies) available for benzoxazoles and Multiple Myeloma

Article	Year
A method for measurement of drug sensitivity of myeloma cells co-cultured with bone marrow stromal cells. Journal of biomolecular screening, 2013, Volume: 18, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzoxazoles; Cell Nucleolus; Cell Survival; Coculture Techniques; Drug Screening Assays, Antitumor; Humans; Mesenchymal Stem Cells; Multiple Myeloma; Quinolinium Compounds; Tumor Cells, Cultured; Tumor Microenvironment	2013
Insight into human protease activated receptor-1 as anticancer target by molecular modelling. SAR and QSAR in environmental research, 2015, Volume: 26, Issue:10 Topics: Antineoplastic Agents; Benzamides; Benzoxazoles; Humans; In Vitro Techniques; Molecular Docking Simulation; Multiple Myeloma; Neural Networks, Computer; Plasma Cells; Protein Binding; Quantitative Structure-Activity Relationship; Receptor, PAR-1; Recurrence	2015
Topoisomerase II-dependent novel antitumor compounds merocil and merodantoin induce apoptosis in Daudi cells. Anti-cancer drugs, 1994, Volume: 5, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Benzoxazoles; Calcium; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Electrophoresis, Agar Gel; Ethylenethiourea; Humans; Multiple Myeloma; Neoplasm Proteins; RNA, Neoplasm; Thiobarbiturates; Topoisomerase II Inhibitors; Tumor Cells, Cultured	1994